Nader Joseph, Metzinger Laurent, Maitrias Pierre, Caus Thierry, Metzinger-Le Meuth Valérie
Department of Cardiac Surgery, Amiens University Hospital, Amiens, France.
HEMATIM EA4666, C.U.R.S, Université de Picardie Jules Verne, 80025, AMIENS Cedex 1, France.
Noncoding RNA Res. 2020 Feb 29;5(2):41-47. doi: 10.1016/j.ncrna.2020.02.005. eCollection 2020 Jun.
Aortic valve stenosis remains the most frequent structural heart disease, especially in the elderly. During the last decade, we noticed an important consideration and a huge number of publications related to the medical and surgical treatment of this disease. However, the molecular aspect of this degenerative issue has also been more widely studied recently. As evidenced in oncologic but also cardiac research fields, the emergence of microRNAs in the molecular screening and follow-up makes them potential biomarkers in the future, for the diagnosis, follow-up and treatment of aortic stenosis. Herein, we present a review on the implication of microRNAs in the aortic valve disease management. After listing and describing the main miRNAs of interest in the field, we provide an outline to develop miRNAs as innovative biomarkers and innovative therapeutic strategies, and describe a groundbreaking pre-clinical study using inhibitors of miR-34a in a pre-clinical model of aortic valve stenosis.
主动脉瓣狭窄仍然是最常见的结构性心脏病，尤其是在老年人中。在过去十年中，我们注意到对这种疾病的医学和外科治疗有了重要的关注以及大量的相关出版物。然而，最近对这个退行性问题的分子层面也进行了更广泛的研究。正如在肿瘤学以及心脏研究领域所证明的那样，微小RNA在分子筛查和随访中的出现使其在未来有可能成为主动脉瓣狭窄诊断、随访和治疗的潜在生物标志物。在此，我们对微小RNA在主动脉瓣疾病管理中的作用进行综述。在列出并描述该领域主要感兴趣的微小RNA后，我们概述了将微小RNA开发为创新生物标志物和创新治疗策略的方法，并描述了一项在主动脉瓣狭窄临床前模型中使用miR-34a抑制剂的开创性临床前研究。
